文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

COVID-19患者抗生素使用:ID-IRI国际调查

Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该国际网络调查由23国82家医院的166名医生参与,评估COVID-19患者抗生素处方模式。结果显示广谱抗生素广泛使用,52.4%受访者联用β-内酰胺类与大环内酯类或氟喹诺酮类,平均疗程7.12天,提示需落实抗菌药物管理原则。

要点

  • COVID-19患者中广谱抗生素使用普遍,需加强抗菌药物管理。
  • 病房患者中29.1%受访者不处方任何抗生素。
  • ICU患者最常处方哌拉西林/他唑巴坦。

核心结论

  • 研究揭示COVID-19患者中广谱抗生素广泛使用,有必要实施抗菌药物管理原则以减少抗生素治疗的负面后果。

研究设计与样本

  • 国际网络调查,由166名来自23个国家82家不同医院的参与医生完成。

主要发现

  • 61.8%(n=102)参与者报告有COVID-19患者抗生素使用本地指南,其中82.9%(n=136)与社区获得性肺炎指南无差异。
  • 启动抗生素的最重要原因是临床表现(均值4.07,SD=1.095,1-5分级)。
  • 抗生素启动时,覆盖非典型病原体需求评分最高(均值2.8,SD=0.99),其次为金黄色葡萄球菌(均值2.67,SD=1.05,双模态量表)。
  • 病房患者中29.1%受访者选择不处方任何抗生素;52.4%(n=87)报告联用β-内酰胺类与大环内酯类或氟喹诺酮类。
  • ICU患者最常处方哌拉西林/他唑巴坦;报告平均抗生素疗程7.12天(SD=2.44)。

临床怎么用

  • 临床应参考本地指南并落实抗菌药物管理原则,避免COVID-19患者不必要的广谱抗生素使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotics may be indicated in patients with COVID-19 due to suspected or confirmed bacterial superinfection. OBJECTIVES: To investigate antibiotic prescribing practices in patients with COVID-19. METHODS: We performed an international web-based survey and investigated the pattern of antibiotic use as reported by physicians involved in treatment of COVID-19. SPSS Statistics version 25 was used for data analysis. RESULTS: The survey was completed by 166 participants from 23 countries and 82 different hospitals. Local guidelines for antibiotic use in COVID-19 patients were reported by 61.8% (n = 102) of participants and for 82.9% (n = 136) they did not differ from local community-acquired pneumonia guidelines. Clinical presentation was recognized as the most important reason for the start of antibiotics (mean score = 4.07 and SD = 1.095 on grading scale from 1 to 5). When antibiotics were started, most respondents rated as the highest the need for coverage of atypical pathogens (mean score = 2.8 and SD = 0.99), followed by Staphylococcus aureus (mean score = 2.67 and SD = 1.05 on bi-modal scale, with values 1 and 2 for disagreement and values 3 and 4 for agreement). In the patients on the ward, 29.1% of respondents chose not to prescribe any antibiotic. Combination of β-lactams and macrolides or fluoroquinolones was reported by 52.4% (n = 87) of respondents. In patients in the ICU, piperacillin/tazobactam was the most commonly prescribed antibiotic. The mean reported duration of antibiotic treatment was 7.12 (SD = 2.44) days. CONCLUSIONS: The study revealed widespread broad-spectrum antibiotic use in patients with COVID-19. Implementation of antimicrobial stewardship principles is warranted to mitigate the negative consequences of antibiotic therapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020. PMID: 32766706. doi:10.1093/jac/dkaa326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。